Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab + lenvatinib + TACE as conversion therapy in potentially resectable hepatocellular carcinoma
ChiCTR2600130619Phase 4Not yet recruiting
- Sponsor
- The Affiliated Hospital of Qingdao University
- Start
- Aug 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of toripalimab in hepatocellular carcinoma (HCC), sponsored by The Affiliated Hospital of Qingdao University. Primary endpoint: Surgical conversion rate. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
toripalimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2600130619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600130619.